Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Conditions
Acute Lymphoblastic Leukaemia · Acute Myeloid Leukaemia · Higher-risk Myelodysplastic Syndromes
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Research Site, Decatur, Illinois, United States
Research Site, New York, New York, United States
Research Site, Chapel Hill, North Carolina, United States
Research Site, Durham, North Carolina, United States
Research Site, Portland, Oregon, United States
Research Site, Houston, Texas, United States
Research Site, Fitzroy, Australia
Research Site, Perth, Australia
Research Site, Toronto, Ontario, Canada
Research Site, Montreal, Quebec, Canada
Research Site, Copenhagen, Denmark
Research Site, Dresden, Germany
Research Site, Frankfurt A. Main, Germany
Research Site, Halle, Germany
Research Site, Heidelberg, Germany
Research Site, München, Germany
Research Site, Ulm, Germany
Research Site, Bologna, Italy
Research Site, Ravenna, Italy
Research Site, Bunkyō City, Japan
Research Site, Kashiwa, Japan
Research Site, Okayama, Japan
Research Site, Seoul, South Korea
Research Site, Seoul, South Korea
Research Site, Seoul, South Korea
Research Site, Edinburgh, United Kingdom
Research Site, London, United Kingdom
Research Site, London, United Kingdom
Research Site, Manchester, United Kingdom
Research Site, Newcastle, United Kingdom